目前对这种新的免疫疗法没有深入研究的方案。但是Lai博士说如果有医药公司感兴趣，会加快对该抗体的评估过程。同时，他还将拓宽埃博拉病毒疗法的适用范围，他正在研发抗体组合，希望能研制出对三种最危险病毒（EBOV，SUDV和Bundibugyo）及Marburg病毒均有效的抗体。Marburg病毒也是一种与埃博拉病毒相关的致命病原体。文献标题：Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.
文章来源：医脉通
作者: bigben446 时间: 2016-2-17 17:32
【标题】：Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses
【作者】：Frei, J. C.; Nyakatura, E. K.; Zak, S. E. (...)
【来源】：Sci Rep, 2016, 6, 19193
【摘要】：Filoviruses (Ebola and Marburg) cause severe hemorrhagic fever. There are five species of ebolavirus; among these, the Ebola (Zaire) and Sudan viruses (EBOV and SUDV, respectively) are highly pathogenic and have both caused recurring, large outbreaks. However, the EBOV and SUDV glycoprotein (GP) sequences are 45% divergent and thus antigenically distinct. Few antibodies with cross-neutralizing properties have been described to date. We used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive toward base epitopes on GP from EBOV and SUDV. These Bis-mAbs exhibit potent neutralization against EBOV and SUDV GP pseudotyped viruses as well as authentic pathogens, and confer a high degree (in one case 100%) post-exposure protection of mice from both viruses. Our studies show that a single agent that targets the GP base epitopes is sufficient for protection in mice; such agents could be included in panfilovirus therapeutic antibody cocktails. http://www.ncbi.nlm.nih.gov/pubmed/26758505?dopt=Abstract